Clinical stage company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health.
Location: France, Ile-de-France, Paris
Total raised: $147.1M
Founded date: 2011
Investors 4
| Date | Name | Website |
| 19.12.2024 | Primo Vent... | primo.vc |
| - | Takeda Ven... | takeda.com |
| - | SymBiosis | symbiosis.... |
| - | Omnes Capi... | omnescapit... |
Funding Rounds 6
| Date | Series | Amount | Investors |
| 12.06.2025 | - | $19M | - |
| 25.06.2020 | Series E | $52.6M | - |
| 04.01.2018 | Series D | $38.61M | - |
| 20.04.2016 | Series C | $16.39M | - |
| 01.05.2014 | Series B | $13.87M | - |
| 23.03.2012 | Series A | $6.63M | - |
Mentions in press and media 24
| Date | Title | Description |
| 23.06.2025 | Enterome: $19 Million Secured To Fund Development Of OncoMimics Immunotherapy To Treat Follicular Lymphoma | Enterome, a clinical-stage company developing first-in-class OncoMimics immunotherapies to treat cancer, announced that it has raised $19 million in new private financing to advance its lead clinical program, EO2463 OncoMimics immunotherapy... |
| 12.06.2025 | Enterome Raises $19M in Funding | Enterome, a Paris, France-based clinical-stage company developing OncoMimics immunotherapies to treat cancer, raised $19M in funding. The round consisted of: $9M from new investor The Institute for Follicular Lymphoma Innovation (IFLI) $10M... |
| 11.12.2024 | Enterome Presents Encouraging Initial Clinical Data on EO4010 in Colorectal Cancer at ESMO IO 2024 | Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver mets, in patients with previously treated microsatellite stable metastatic colorectal cancer (mCRC)... |
| 06.11.2024 | Enterome to Present New Clinical Data and Biomarker Findings for EO2463 at the 2024 American Society of Hematology (ASH) Annual Meeting | Two poster presentations to feature novel data from the Phase 1/2 SIDNEY trial of EO2463 in indolent Non-Hodgkin Lymphoma (iNHL), highlighting initial data from Cohort 2 as monotherapy in a “watch-and-wait” setting, and findings on a predic... |
| 24.05.2024 | Enterome Highlights High Complete Response Rate in Clinical Study of EO2463 for Indolent Non-Hodgkin Lymphoma at ASCO 2024 | - Beneficial clinical responses observed with EO2463 monotherapy already at 6 weeks and complete response rate of 78% in patients treated with EO2463 upon addition of lenalidomide ± rituximab - EO2463 rapidly expands memory CD8+ T cells spe... |
| 25.04.2024 | Enterome to Present Clinical Data on EO2463 in B-cell Lymphoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | Poster presentation to highlight updated data from ongoing Phase 1/2 of EO2463 monotherapy and in combination with lenalidomide and/or rituximab in indolent non-Hodgkin lymphoma (NHL) PARIS, April 25, 2024 (GLOBE NEWSWIRE) -- Enterome, a cl... |
| 17.04.2024 | Enterome Announces Successful Completion of Phase 2 ROSALIE Study of EO2401 in Recurrent Glioblastoma | EO2401, a pioneering OncoMimics™ peptide-based immunotherapy, has demonstrated rapid activation and significant expansion of existing effector memory T cells against tumor-associated driver antigens due to their strong cross-reactivity with... |
| 06.03.2024 | Enterome Announces Upcoming Presentation on OncoMimics™ Approach to Cancer Immunotherapy at the AACR Annual Meeting 2024 | - |
| 13.11.2023 | Enterome to Present Updated Data From Phase 1/2 ROSALIE Trial of its Peptide-Based Immunotherapy EO2401 in Recurrent Glioblastoma at SNO 2023 | Oral Presentation at SNO will feature updated results from the Phase 1/2 EOGBM1-18/ROSALIE study PARIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liqu... |
| 31.05.2023 | Enterome announces sustained positive clinical outcomes with EO2401, its lead OncoMimics™ immunotherapy, in combination therapy in Glioblastoma at ASCO | /EIN News/ -- Updated clinical data highlight promising efficacy and sustained CD8+ T cell expansion Early data from final cohort could provide validation of the EO2401 + nivolumab + bevacizumab combination outcome Paves the way to next pot... |
Show more